Recent advances in polymer-based nanoformulations for enhancing oral drug delivery in diabetes

3. October 2024

Diabetes is a long-term metabolic disorder caused by issues with insulin production or response in the body. This leads to...

Encapsulation of bioactive compounds in foods for diabetics – sources, encapsulation technologies, market trends and future perspectives – A systematic review

18. August 2024

Diabetes is a metabolic disorder characterized by hyperglycemia and is a disease with an increasing prevalence. Hyperglycemia triggers abnormalities in...

Experimental Investigation on Efficacy of Eudragit RS 100 Polymer in Prolonging Glibenclamide Release by Intragastric Floating Microsphere Formulation and Physicochemical Evaluation

27. July 2024

Abstract Background: The amalgamation of targeted transportation and enhancement of the release profile of the active pharmaceutical ingredient is a...

Preparation of nanoparticle and nanoemulsion formulations containing repaglinide and determination of pharmacokinetic parameters in rats

21. July 2024

Abstract Repaglinide (RPG) belongs to the class of drugs known as meglitinides and is used for improving and maintaining glycemic...

Formulation and dermal delivery of a new active pharmaceutical ingredient in an in vitro wound model for the treatment of chronic ulcers

1. July 2024

The aim of this study was to investigate dermal delivery of the new active pharmaceutical ingredient (API) TOP-N53 into diabetic...

Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats

24. May 2024

Abstract Liraglutide (LIRA) is a glucagon-like peptide-1 (GLP-1) receptor agonist renowned for its efficacy in treating type 2 diabetes mellitus...

Advancements in application of chitosan and cyclodextrins in biomedicine and pharmaceutics: recent progress and future trends

8. May 2024

Abstract The global community is faced with numerous health concerns such as cancer, cardiovascular and neurological diseases, diabetes, joint pain,...

Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide

25. January 2024

Semaglutide is the first oral glucagon-like peptide-1 (GLP-1) analog commercially available for the treatment of type 2 diabetes. In this work, semaglutide...

Design, development and scale up studies of metformin hydrochloride multiparticulate system: A promising alternative to large size tablet

23. January 2024

Metformin hydrochloride (MH) is prescribed for treating diabetes mellitus. The most popular dosage form, viz., tablets has a bulky nature...

Development of a multi-component gastroretentive expandable drug delivery system (GREDDS) for personalized administration of metformin

30. December 2023

Objectives Efficacy and compliance of type II diabetes treatment would greatly benefit from dosage forms providing controlled release of metformin...

Diabetes